Navigation Links
Landauer, Inc. Reports Fiscal 2009 Third Quarter Results

GLENWOOD, Ill., Aug. 4 /PRNewswire-FirstCall/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation monitoring services, today reported financial results for the three and nine months ended June 30, 2009.

Fiscal 2009 Third Quarter Highlights

  • Revenue grew 7 percent to $23.5 million on continued global demand for InLight products and increased domestic badge revenues.
  • Gross profit grew 4 percent to $15.6 million on increased revenue.
  • Effective tax rate declined to 30 percent due primarily to changes in Illinois state tax law and tax benefit of funding frozen pension plan.
  • Net income grew 13 percent to $6.5 million, or $0.70 per diluted share.

"We are pleased with this quarter's financial results, which were driven substantially by InLight sales both domestically and abroad," stated Bill Saxelby, President and CEO of Landauer. "During the quarter we made significant InLight product placements across several markets we have targeted for growth including the U.S. military, the first responder market, and patient monitoring. In addition, we continued to drive global expansion through the continuation of our relationship with Health Canada and placement of InLight products into Southeast Asia through our joint venture with Nagase-Landauer."

"The continued acceptance of our InLight suite of products, success of our international expansion initiative and adoption of our offerings in the medical, nuclear and military markets affirm the long-term growth prospects for our business. We have also made significant progress in our current systems initiative, delivering successfully on several important milestones during the quarter."

Saxelby noted, "We are pleased with the progress we've made in fiscal 2009. Landauer's performance demonstrates the success of our continued focus on executing our strategic priorities: optimizing our core business, driving competitive growth, and pursuing strategic expansion. Our strong cash flow generation has provided us with the sufficient capital to execute on all three of our strategic priorities."

Revenue Growth Continues

Revenues for the third fiscal quarter of 2009 were $23.5 million, a 7 percent increase compared with the $21.9 million reported for the third fiscal quarter of 2008. Domestic revenue increased 5 percent, or $0.7 million, on InLight product demand and growth in domestic badge revenue. Organic international revenue growth of approximately 27 percent was offset by the impact of the strengthening of the dollar against most foreign currencies, which reduced revenue by approximately $0.7 million in the quarter, resulting in a reported increase of 14 percent, or $0.8 million.

Cost of sales increased 14 percent for the quarter due to increased cost of materials to support growth in InLight products sales. Gross margin declined to 66 percent from 68 percent in the year ago period due to the revenue mix. Selling, general and administrative expenses for the third fiscal quarter of 2009 increased 2 percent, or $141,000, driven primarily by increased expense spending to replace the Company's information technology systems that support customer relationship management and the order-to-cash cycle.

The effective tax rate for the third fiscal quarter of 2009 decreased to 30 percent compared with 35 percent for the third fiscal quarter of 2008. The reduction is due primarily to a change in the state tax rate driven by changes in the Illinois state tax law and the tax benefit of funding the frozen pension plan. Net income for the fiscal quarter ended June 30, 2009 was $6.5 million, an increase of 13 percent compared with $5.8 million for the third fiscal quarter of 2008. The resulting diluted earnings per share for the third fiscal quarter of 2009 were $0.70 compared with $0.62 for the third fiscal quarter of 2008.

For the nine months ended on June 30, 2009, revenues increased 5 percent to $70.9 million versus $67.5 million at this time last year. The gross profit margin was 67 percent versus 68 percent from last year's nine-month period ended June 30, 2008. Selling, general and administrative expenses for the first nine months of fiscal 2009 increased $87,000 compared to the first nine months of fiscal 2008.

On February 5, 2009, the Board of Directors approved changes to the Company's retirement benefit plans to transition from a defined benefit plan to a defined contribution approach to retirement benefits. As a result of the changes, the Company recognized $2.2 million ($1.5 million after-tax) of non-recurring pension curtailment and transition costs during the second fiscal quarter of 2009. In addition, the Company initiated a management reorganization plan to strengthen selected roles in the organization. As a result, the Company recognized $489,000 ($322,000 after-tax) of non-recurring reorganization charges during the second fiscal quarter of 2009.

Year-to-date net income was $18.1 million, an increase of 3.5 percent from $17.5 million in the prior year period. Earnings per diluted share were $1.94 compared with $1.89 for the same period last year. Excluding the effect of the pension curtailment and transition costs and the reorganization charges, net income for the first nine months of fiscal 2009 was $19.9 million, or $ 2.14 per diluted share.

Solid Financial Position

Landauer ended the third fiscal quarter of 2009 with total assets of $121.3 million and working capital of $32.2 million. At June 30, 2009, Landauer continued to be debt free. During the quarter, the Company negotiated an amendment to its credit agreement to increase permitted borrowings from $15 million to $30 million and to extend the expiration to June 2011. Cash provided by operating activities was $18.1 million, a decline of $6.2 million from the first nine months of fiscal 2008. The decline is due primarily to $6.5 million in incremental payments to the Company's defined benefit pension plan to bring the plan to a fully funded status in conjunction with the actions to freeze the plan.

Fiscal 2009 Outlook

Saxelby concluded, "We believe Landauer is positioned to generate strong performance as a result of our diverse market and product opportunities, financial discipline, and strong industry positioning. We have made solid progress in executing against our fiscal year goals for the InLight family of products and have closed the majority of our targeted opportunities. Accordingly, we will experience lower growth comparisons in the fourth quarter; however, we anticipate we will reach our annual guidance ranges."

The Company's business plan for fiscal 2009 currently anticipates aggregate revenue growth for the year to be in the range of 3 - 5 percent. The Company currently anticipates a net income increase in the range of 6 - 8 percent, prior to the $1.8 million after-tax impact of the pension curtailment and transition costs and management reorganization charges.

Conference Call Details

Landauer has scheduled its third quarter conference call for investors over the Internet on Tuesday, August 4, 2009 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). To participate, callers should dial 877-941-7133 (within the United States and Canada) or 480-629-9786 (international calls), and reference the conference ID #4123060, about 10 minutes before the presentation. To listen to a webcast on the Internet, please go to the Company's website at at least 15 minutes early to register, download and install any necessary audio software. Investors may access a replay of the call by dialing 800-406-7325 (within the United States and Canada) or 303-590-3030 (international calls) passcode 4123060#, which will be available until September 1, 2009. The replay of the call will remain available on Landauer's website for 90 days.

About Landauer

Landauer is the world's leading provider of technical and analytical services to determine occupational and environmental radiation exposure. For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees. Landauer's services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from clients, and the analysis and reporting of exposure findings. The Company provides its services to approximately 1.6 million people in the United States, Japan, France, the United Kingdom, Brazil, Canada, China, Australia, Mexico and other countries.

Safe Harbor Statement

Some of the information shared here (including, in particular, the section titled "Fiscal 2009 Outlook") constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and uncertainties associated with the Company's development and introduction of new technologies in general; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; the costs associated with the Company's research and business development efforts; the usefulness of older technologies; the effectiveness of changes and upgrades to and costs associated with the Company's information systems; the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company's long-lived assets or business units relative to future cash flows; changes in pricing of products and services; changes in postal and delivery practices; the Company's business plans; anticipated revenue and cost growth; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the cost of obligations under the Company's benefit plans; and pending accounting pronouncements. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company's business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses. You can find more information by reviewing the "Risk Factors" section in the Company's Annual Report on Form 10-K for the year ended September 30, 2008, and other reports filed by the Company from time to time with the Securities and Exchange Commission.

Financial Tables Follow

                  Fiscal 2009 Third Quarter Financial Highlights
             (unaudited, amounts in thousands, except per share data)

                                       Three months ended Nine months ended
                                             June 30,        June 30,
                                             --------        --------
                                          2009     2008     2009     2008
                                          ----     ----     ----     ----
    Net revenues                       $23,468  $21,902  $70,860  $67,454

    Costs and expenses:
      Cost of sales                      7,874    6,929   23,393   21,645
      Selling, general and
       administrative                    6,612    6,471   19,793   19,706
      Net defined benefit plan
       curtailment loss and
       transition costs                      -        -    2,236        -
      Reorganization charges                 -        -      489        -
                                           ---      ---      ---      ---
                                        14,486   13,400   45,911   41,351

    Operating income                     8,982    8,502   24,949   26,103

    Other income, net                      459      633    1,728    1,918
                                           ---      ---    -----    -----

    Income before taxes                  9,441    9,135   26,677   28,021
    Income taxes                         2,800    3,214    8,353   10,259
                                         -----    -----    -----   ------

    Income before minority
     interest                            6,641    5,921   18,324   17,762
    Minority interest                       95      128      208      263
                                            --      ---      ---      ---

    Net income                          $6,546   $5,793  $18,116  $17,499
                                        ======   ======  =======  =======

    Net income per common share:
      Basic                              $0.70    $0.63    $1.95    $1.90
                                         =====    =====    =====    =====
      Weighted average basic shares
       outstanding                       9,304    9,244    9,279    9,209
                                         =====    =====    =====    =====

      Diluted                            $0.70    $0.62    $1.94    $1.89
                                         =====    =====    =====    =====
      Weighted average diluted           9,347    9,307    9,326    9,273
       shares outstanding                =====    =====    =====    =====

                      Summary Consolidated Balance Sheets
                       (unaudited, amounts in thousands)

                                              June 30, September 30,
                                                  2009         2008
                                                  ----         ----
     Current Assets:
          Cash and cash equivalents            $32,256      $33,938
          Receivables, net of allowances        24,220       19,738
          Other current assets                  11,029       15,053
                                                ------       ------
     Total current assets                       67,505       68,729

     Net property, plant and equipment          23,678       20,185
     Equity in joint venture                     6,629        5,796
     Goodwill and other intangible assets,
      net of amortization                       17,730       18,102
     Dosimetry devices, net of amortization      4,599        4,454
     Other assets                                1,148        1,424
                                                 -----        -----
     TOTAL ASSETS                             $121,289     $118,690
                                              ========     ========

     Current Liabilities:
          Accounts payable                      $3,096         $981
          Dividends payable                      4,980        4,686
          Deferred contract revenue             16,844       15,626
          Other current liabilities             10,365       12,931
                                                ------       ------
     Total current liabilities                  35,285       34,224
     Non-current Liabilities:
          Pension and postretirement
           obligations                           6,160        8,609
          Deferred income taxes                  4,943        4,622
          Other non-current liabilities          1,033          935
                                                 -----          ---
     Total non-current liabilities              12,136       14,166

     Minority interest in subsidiary               582          545

     Stockholders' equity                       73,286       69,755
                                                ------       ------
                                              $121,289     $118,690
                                              ========     ========

SOURCE Landauer, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2009 Results
2. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Second Quarter 2009 Results
3. Landauer, Inc. Declares Regular Cash Dividend
4. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2009 Results
5. Landauer, Inc. Increases Regular Cash Dividend and Declares First Quarter Payment
6. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2008 Results
7. Landauer, Inc. Declares Regular Cash Dividend
8. Landauer, Inc. Declares Regular Cash Dividend
9. Landauer, Inc. Reports Record Results for Second Quarter
10. Landauer, Inc. Declares Regular Cash Dividend
11. Landauer, Inc. Reports Strong Fiscal 2008 First Quarter Results
Post Your Comments:
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack ... trailer titles work with any font, giving users limitless opportunities to stylize and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
Breaking Medicine Technology: